Titel: Prof. Eberhart Zrenner
Startdatum: Sep 23 2019
Startzeit: 06:15 pm
Endzeit: 07:15 pm
Organisator: PD Dr. Goran Angelovski
Ort: Max Planck House Lecture Hall

Prof. Dr. Eberhart Zrenner
Werner Reichardt Centrum für Integrative Neurowissenschaften (CIN)
Institute for Ophthalmic Research
Centre for Ophthalmology
University of Tübingen

Restitution of Vision in Blinding Retinal Diseases: Gene Replacement Therapy and Retinal Prosthesis

There are two effective prevention and treatment approaches available to certain groups of patients with Inherited Retinal Dystrophies (IRD):
Gene replacement therapy where viral or non-viral vectors are used to restore insufficient or lacking gene function as a result of pathogenic mutation, is especially attractive for treatment in recessively inherited diseases.  Results of the first gene supplementation therapy  in Germany for an inherited eye disease performed by the RD-CURE consortium in Tübingen in nine patients with CNGA3-linked Achromatopsia will be presented, in addition to studies in mice and non-human-primates. The  rAAV.hCNGA3 vector was well tolerated and  lead neither to any unexpected  nor to any serious adverse events; exploration of function supports the notion that CNGA3-linked achromatopsia can be treated by gene supplementation therapy.
Electronic retinal implants have made rapid progress in recent years with remarkable results concerning visual localization of objects, mobility, even reading and face recognition in some cases (Zrenner et al 2011, Zrenner, 2013; Stingl et al. 2015, 2017). Results with subretinal implant Alpha that utilizes 1600 light sensitive photodiodes and amplifiers, each connected to an electrode, placed beneath the retina, contacting the functional input of the retina on the photoreceptor side (Stingl et al. Vis. Res. 2015, 2017) will be presented. Psychophysical and subjective data in more than 70 patients show that Retina Implant Alpha is reliable and well tolerated, and partially restores visual functions in the majority of patients.
In summary: Gene replacement therapy is the choice for patients in early stages of the disease with sufficient cells still  present to be treated and thereby protected from cell death, while electronic retinal prostheses are applicable to those who have lost vision to a level of bare light perception or less.

Host: Prof. Zhaoping Li